Postoperative Radiotherapy for Resected Stage IIIA–N2 Non-small-cell Lung Cancer: a Review of Outcomes
Objective: To review the outcomes of postoperative radiotherapy (PORT) using three-dimensional conformal techniques in patients with resected pathological N2 (pN2) non-small-cell lung cancer (NSCLC). Methods: Consecutive patients who underwent PORT for resected pN2 NSCLC were retrospectively reviewe...
Gespeichert in:
Veröffentlicht in: | Hong Kong journal of radiology : HKJR = Xianggang fang she ke yi xue za zhi 2018-12, Vol.21 (4), p.241-248 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 248 |
---|---|
container_issue | 4 |
container_start_page | 241 |
container_title | Hong Kong journal of radiology : HKJR = Xianggang fang she ke yi xue za zhi |
container_volume | 21 |
creator | Lam, YT Lim, FMY Tong, M Cheng, ACK |
description | Objective: To review the outcomes of postoperative radiotherapy (PORT) using three-dimensional conformal techniques in patients with resected pathological N2 (pN2) non-small-cell lung cancer (NSCLC). Methods: Consecutive patients who underwent PORT for resected pN2 NSCLC were retrospectively reviewed. Adjuvant chemotherapy was given before PORT. Locoregional and systemic recurrences, disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan-Meier method. Factors associated with DFS and OS were determined using the log-rank test. Results: Eight men and seven women aged 38 to 76 (median, 65) years were included. All had stage IIIA cancer and underwent lobectomy. 12 and three patients had single and multiple mediastinal lymph node station involvement, respectively. The median numbers of resected lymph nodes and lymph node stations were 6 and 4, respectively. Only five patients underwent systematic nodal dissection or sampling. 13 patients underwent adjuvant chemotherapy. The median follow-up period was 31.9 months. Actuarial locoregional control was 100% at 1 year, 92.4% at 2 years, and 82.0% at 3 years. Ten patients had recurrence; all had distant metastases as the first failure event. The median time to recurrence was 12.6 months. DFS was 66.5% at 1 year, 46.5% at 2 years, and 40.0% at 3 years; the median DFS was 14.9 months. OS was 93.5% at 1 year, 66.5% at 2 years, and 51.5% at 3 years; the median OS was 42.4 months. There were nine deaths; eight were cancer-related and one was of unknown cause. Multiple pN2 lymph node station involvement was the only variable that was significant for both DFS and OS. Compared with patients with single pN2 lymph node station involvement, patients with multiple pN2 lymph node station involvement had shorter median DFS (10.9 months vs. 29.2 months, p = 0.008) and median OS (12.1 months vs. 54.1 months, p = 0.003). No patient had grade 3 or above toxicities. Conclusion: PORT using modern techniques and dose fractionation for patients with resected pN2 NSCLC was well tolerated and resulted in a high locoregional control rate, but the rate of distant metastasis remained high. Patients with multiple pN2 lymph node station involvement had worse survival. Author affiliation(s): YT Lam, FMY Lim, ACK Cheng: Department of Oncology, Princess Margaret Hospital, Laichikok, Hong Kong M Tong: Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong |
doi_str_mv | 10.12809/hkjr1816824 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2785286730</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2785286730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c188t-972d30947ec8612db4f802a9eea4dfe015a4fd5d69f9c32ceb9b346c42ae03243</originalsourceid><addsrcrecordid>eNpNUEtOwzAUtBBIVNAdB7DEloB_dWx2VcUnUtWiAuvIdZ7blDQOdlLUHXfghpyEiLJgNTPSfKRB6IKSa8oU0Tfrt02gikrFxBEaME7SREhGjnvOGE-kpPoUDWPcEEJYqgWh6QCtn3xsfQPBtOUO8MIUpW_XvWz22PmAFxDBtlDg59asAGdZNv7-_JoxPPN1EremqhILVYWnXb3CE1NbCLfY9LFdCR_YOzzvWuu3EM_RiTNVhOEfnqHX-7uXyWMynT9kk_E0sVSpNtEpKzjRIgWrJGXFUjhFmNEARhQOCB0Z4YpRIbXTljMLS73kQlrBDBDOBD9Dl4feJvj3DmKbb3wX6n4yZ6kaMSVTTnrX1cFlg48xgMubUG5N2OeU5L935v_u5D9olGjV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785286730</pqid></control><display><type>article</type><title>Postoperative Radiotherapy for Resected Stage IIIA–N2 Non-small-cell Lung Cancer: a Review of Outcomes</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lam, YT ; Lim, FMY ; Tong, M ; Cheng, ACK</creator><creatorcontrib>Lam, YT ; Lim, FMY ; Tong, M ; Cheng, ACK ; Department of Oncology, Princess Margaret Hospital, Laichikok, Hong Kong</creatorcontrib><description>Objective: To review the outcomes of postoperative radiotherapy (PORT) using three-dimensional conformal techniques in patients with resected pathological N2 (pN2) non-small-cell lung cancer (NSCLC). Methods: Consecutive patients who underwent PORT for resected pN2 NSCLC were retrospectively reviewed. Adjuvant chemotherapy was given before PORT. Locoregional and systemic recurrences, disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan-Meier method. Factors associated with DFS and OS were determined using the log-rank test. Results: Eight men and seven women aged 38 to 76 (median, 65) years were included. All had stage IIIA cancer and underwent lobectomy. 12 and three patients had single and multiple mediastinal lymph node station involvement, respectively. The median numbers of resected lymph nodes and lymph node stations were 6 and 4, respectively. Only five patients underwent systematic nodal dissection or sampling. 13 patients underwent adjuvant chemotherapy. The median follow-up period was 31.9 months. Actuarial locoregional control was 100% at 1 year, 92.4% at 2 years, and 82.0% at 3 years. Ten patients had recurrence; all had distant metastases as the first failure event. The median time to recurrence was 12.6 months. DFS was 66.5% at 1 year, 46.5% at 2 years, and 40.0% at 3 years; the median DFS was 14.9 months. OS was 93.5% at 1 year, 66.5% at 2 years, and 51.5% at 3 years; the median OS was 42.4 months. There were nine deaths; eight were cancer-related and one was of unknown cause. Multiple pN2 lymph node station involvement was the only variable that was significant for both DFS and OS. Compared with patients with single pN2 lymph node station involvement, patients with multiple pN2 lymph node station involvement had shorter median DFS (10.9 months vs. 29.2 months, p = 0.008) and median OS (12.1 months vs. 54.1 months, p = 0.003). No patient had grade 3 or above toxicities. Conclusion: PORT using modern techniques and dose fractionation for patients with resected pN2 NSCLC was well tolerated and resulted in a high locoregional control rate, but the rate of distant metastasis remained high. Patients with multiple pN2 lymph node station involvement had worse survival. Author affiliation(s): YT Lam, FMY Lim, ACK Cheng: Department of Oncology, Princess Margaret Hospital, Laichikok, Hong Kong M Tong: Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong</description><identifier>ISSN: 2223-6619</identifier><identifier>EISSN: 2307-4620</identifier><identifier>DOI: 10.12809/hkjr1816824</identifier><language>eng</language><publisher>Hong Kong: Hong Kong Academy of Medicine</publisher><subject>Chemotherapy ; Clinical outcomes ; Lung cancer ; Lymphatic system ; Postoperative period ; Radiation therapy</subject><ispartof>Hong Kong journal of radiology : HKJR = Xianggang fang she ke yi xue za zhi, 2018-12, Vol.21 (4), p.241-248</ispartof><rights>2018. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Lam, YT</creatorcontrib><creatorcontrib>Lim, FMY</creatorcontrib><creatorcontrib>Tong, M</creatorcontrib><creatorcontrib>Cheng, ACK</creatorcontrib><creatorcontrib>Department of Oncology, Princess Margaret Hospital, Laichikok, Hong Kong</creatorcontrib><title>Postoperative Radiotherapy for Resected Stage IIIA–N2 Non-small-cell Lung Cancer: a Review of Outcomes</title><title>Hong Kong journal of radiology : HKJR = Xianggang fang she ke yi xue za zhi</title><description>Objective: To review the outcomes of postoperative radiotherapy (PORT) using three-dimensional conformal techniques in patients with resected pathological N2 (pN2) non-small-cell lung cancer (NSCLC). Methods: Consecutive patients who underwent PORT for resected pN2 NSCLC were retrospectively reviewed. Adjuvant chemotherapy was given before PORT. Locoregional and systemic recurrences, disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan-Meier method. Factors associated with DFS and OS were determined using the log-rank test. Results: Eight men and seven women aged 38 to 76 (median, 65) years were included. All had stage IIIA cancer and underwent lobectomy. 12 and three patients had single and multiple mediastinal lymph node station involvement, respectively. The median numbers of resected lymph nodes and lymph node stations were 6 and 4, respectively. Only five patients underwent systematic nodal dissection or sampling. 13 patients underwent adjuvant chemotherapy. The median follow-up period was 31.9 months. Actuarial locoregional control was 100% at 1 year, 92.4% at 2 years, and 82.0% at 3 years. Ten patients had recurrence; all had distant metastases as the first failure event. The median time to recurrence was 12.6 months. DFS was 66.5% at 1 year, 46.5% at 2 years, and 40.0% at 3 years; the median DFS was 14.9 months. OS was 93.5% at 1 year, 66.5% at 2 years, and 51.5% at 3 years; the median OS was 42.4 months. There were nine deaths; eight were cancer-related and one was of unknown cause. Multiple pN2 lymph node station involvement was the only variable that was significant for both DFS and OS. Compared with patients with single pN2 lymph node station involvement, patients with multiple pN2 lymph node station involvement had shorter median DFS (10.9 months vs. 29.2 months, p = 0.008) and median OS (12.1 months vs. 54.1 months, p = 0.003). No patient had grade 3 or above toxicities. Conclusion: PORT using modern techniques and dose fractionation for patients with resected pN2 NSCLC was well tolerated and resulted in a high locoregional control rate, but the rate of distant metastasis remained high. Patients with multiple pN2 lymph node station involvement had worse survival. Author affiliation(s): YT Lam, FMY Lim, ACK Cheng: Department of Oncology, Princess Margaret Hospital, Laichikok, Hong Kong M Tong: Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong</description><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Postoperative period</subject><subject>Radiation therapy</subject><issn>2223-6619</issn><issn>2307-4620</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpNUEtOwzAUtBBIVNAdB7DEloB_dWx2VcUnUtWiAuvIdZ7blDQOdlLUHXfghpyEiLJgNTPSfKRB6IKSa8oU0Tfrt02gikrFxBEaME7SREhGjnvOGE-kpPoUDWPcEEJYqgWh6QCtn3xsfQPBtOUO8MIUpW_XvWz22PmAFxDBtlDg59asAGdZNv7-_JoxPPN1EremqhILVYWnXb3CE1NbCLfY9LFdCR_YOzzvWuu3EM_RiTNVhOEfnqHX-7uXyWMynT9kk_E0sVSpNtEpKzjRIgWrJGXFUjhFmNEARhQOCB0Z4YpRIbXTljMLS73kQlrBDBDOBD9Dl4feJvj3DmKbb3wX6n4yZ6kaMSVTTnrX1cFlg48xgMubUG5N2OeU5L935v_u5D9olGjV</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Lam, YT</creator><creator>Lim, FMY</creator><creator>Tong, M</creator><creator>Cheng, ACK</creator><general>Hong Kong Academy of Medicine</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20181201</creationdate><title>Postoperative Radiotherapy for Resected Stage IIIA–N2 Non-small-cell Lung Cancer: a Review of Outcomes</title><author>Lam, YT ; Lim, FMY ; Tong, M ; Cheng, ACK</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c188t-972d30947ec8612db4f802a9eea4dfe015a4fd5d69f9c32ceb9b346c42ae03243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Postoperative period</topic><topic>Radiation therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lam, YT</creatorcontrib><creatorcontrib>Lim, FMY</creatorcontrib><creatorcontrib>Tong, M</creatorcontrib><creatorcontrib>Cheng, ACK</creatorcontrib><creatorcontrib>Department of Oncology, Princess Margaret Hospital, Laichikok, Hong Kong</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Hong Kong journal of radiology : HKJR = Xianggang fang she ke yi xue za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lam, YT</au><au>Lim, FMY</au><au>Tong, M</au><au>Cheng, ACK</au><aucorp>Department of Oncology, Princess Margaret Hospital, Laichikok, Hong Kong</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postoperative Radiotherapy for Resected Stage IIIA–N2 Non-small-cell Lung Cancer: a Review of Outcomes</atitle><jtitle>Hong Kong journal of radiology : HKJR = Xianggang fang she ke yi xue za zhi</jtitle><date>2018-12-01</date><risdate>2018</risdate><volume>21</volume><issue>4</issue><spage>241</spage><epage>248</epage><pages>241-248</pages><issn>2223-6619</issn><eissn>2307-4620</eissn><abstract>Objective: To review the outcomes of postoperative radiotherapy (PORT) using three-dimensional conformal techniques in patients with resected pathological N2 (pN2) non-small-cell lung cancer (NSCLC). Methods: Consecutive patients who underwent PORT for resected pN2 NSCLC were retrospectively reviewed. Adjuvant chemotherapy was given before PORT. Locoregional and systemic recurrences, disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan-Meier method. Factors associated with DFS and OS were determined using the log-rank test. Results: Eight men and seven women aged 38 to 76 (median, 65) years were included. All had stage IIIA cancer and underwent lobectomy. 12 and three patients had single and multiple mediastinal lymph node station involvement, respectively. The median numbers of resected lymph nodes and lymph node stations were 6 and 4, respectively. Only five patients underwent systematic nodal dissection or sampling. 13 patients underwent adjuvant chemotherapy. The median follow-up period was 31.9 months. Actuarial locoregional control was 100% at 1 year, 92.4% at 2 years, and 82.0% at 3 years. Ten patients had recurrence; all had distant metastases as the first failure event. The median time to recurrence was 12.6 months. DFS was 66.5% at 1 year, 46.5% at 2 years, and 40.0% at 3 years; the median DFS was 14.9 months. OS was 93.5% at 1 year, 66.5% at 2 years, and 51.5% at 3 years; the median OS was 42.4 months. There were nine deaths; eight were cancer-related and one was of unknown cause. Multiple pN2 lymph node station involvement was the only variable that was significant for both DFS and OS. Compared with patients with single pN2 lymph node station involvement, patients with multiple pN2 lymph node station involvement had shorter median DFS (10.9 months vs. 29.2 months, p = 0.008) and median OS (12.1 months vs. 54.1 months, p = 0.003). No patient had grade 3 or above toxicities. Conclusion: PORT using modern techniques and dose fractionation for patients with resected pN2 NSCLC was well tolerated and resulted in a high locoregional control rate, but the rate of distant metastasis remained high. Patients with multiple pN2 lymph node station involvement had worse survival. Author affiliation(s): YT Lam, FMY Lim, ACK Cheng: Department of Oncology, Princess Margaret Hospital, Laichikok, Hong Kong M Tong: Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong</abstract><cop>Hong Kong</cop><pub>Hong Kong Academy of Medicine</pub><doi>10.12809/hkjr1816824</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2223-6619 |
ispartof | Hong Kong journal of radiology : HKJR = Xianggang fang she ke yi xue za zhi, 2018-12, Vol.21 (4), p.241-248 |
issn | 2223-6619 2307-4620 |
language | eng |
recordid | cdi_proquest_journals_2785286730 |
source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Chemotherapy Clinical outcomes Lung cancer Lymphatic system Postoperative period Radiation therapy |
title | Postoperative Radiotherapy for Resected Stage IIIA–N2 Non-small-cell Lung Cancer: a Review of Outcomes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A07%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postoperative%20Radiotherapy%20for%20Resected%20Stage%20IIIA%E2%80%93N2%20Non-small-cell%20Lung%20Cancer:%20a%20Review%20of%20Outcomes&rft.jtitle=Hong%20Kong%20journal%20of%20radiology%20:%20HKJR%20=%20Xianggang%20fang%20she%20ke%20yi%20xue%20za%20zhi&rft.au=Lam,%20YT&rft.aucorp=Department%20of%20Oncology,%20Princess%20Margaret%20Hospital,%20Laichikok,%20Hong%20Kong&rft.date=2018-12-01&rft.volume=21&rft.issue=4&rft.spage=241&rft.epage=248&rft.pages=241-248&rft.issn=2223-6619&rft.eissn=2307-4620&rft_id=info:doi/10.12809/hkjr1816824&rft_dat=%3Cproquest_cross%3E2785286730%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785286730&rft_id=info:pmid/&rfr_iscdi=true |